Covid Vaccine Race

The announcement aligns with an FDA and CDC statement against the need for booster doses.

In the second installment of an interview, members of the FlowMetric Life Sciences' leadership discuss how their technology might aid possible COVID-19 vaccine booster shots, how immunocompromised patients respond to vaccines, and other vaccines where their platform may be used.

The Sinovac developed vaccine could greatly aid in the global inoculation effort.

Two doses of the Pfizer or AstraZeneca vaccines generated high sero-neutralization against the strain.

While the efficacy of SARS-CoV-2 vaccines have been demonstrated, a lack of data is present for patients with cancer.

FlowMetric, Inc., discusses its VaxEffect, an immune monitoring platform and how it can be used to measure COVID-19 vaccine responses.

Benefits were also observed among adults aged 18 to 49, with adults over 65 seeing the most benefit.

A single dose of mRNA vaccine proved 81% effective against a SARS-CoV-2 infection.

The therapy demonstrated an efficacy of 65.2% against the Delta variant.

New data suggest countries with limited vaccine supplies may not need to immediately vaccinate all members of low-risk households.

The activity was higher than what was recently observed for the South African variant.

94% of the participants in the study developed COVID-19 antibodies.

The Sinovac developed vaccine generated antibodies against SARS-CoV-2 in a phase 1/2 trial.

AstraZeneca’s COVID-19 vaccine was safe and immunogenic for people with HIV who are well-controlled on antiretroviral therapy, a study has shown.

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

As many vaccines are under Emergency Use Authorization (EUA), understanding the incidence rates of adverse events is critical to providing education and awareness, while working to increase distribution.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

With a small number of heart-related adverse effects in younger people, the US Food and Drug Administration (FDA) will move towards a warning statement for Pfizer and Moderna vaccines.

A new report from a Qatari pilot program showed vaccines are highly effective against COVID-19, but they do not completely eliminate risk.

The benefits of mRNA vaccinations were determined to still clearly outweigh the risks in adolescents and young adults.

According to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.

Africa sees third wave as only 1% of the population is fully vaccinated.

CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity.

Investigators in Brazil attribute Trichosporon asahii fungemia in critically ill COVID-19 patients to “overexposure” to antibiotics and corticosteroids.

A discussion surrounding Novavax’s NVX-CoV2373 with Lisa Dunkle, MD.

With the company reporting its data today and it applying for authorization with regulatory bodies internationally, and later this year with the US Food and Drug Administration (FDA), what does the prospect of this new vaccine mean to people in the US and internationally?

India plans to manufacture over 2 billion doses of COVID-19 vaccines by December

Experts suggest the vaccine, if regulated by the FDA, would benefit the US as a booster dose to combat waning immunity against emerging variants.